Swiss pharmaceutical company Roche has announced that pertuzumab has reached its primary endpoint in a Phase III study to test it as a treatment for breast cancer.
The trial showed that pertuzumab in combination with Herceptin (trastuzumab) and docetaxel chemotherapy helped patients with breast cancer live longer, without the disease getting worse.
Roche plans to seek approval for the drug, which works by inhibiting growth of cancer-causing protein HER2, in the US and Europe later this year.
Roche chief medical officer and head of global product development Hal Barron said, “These results with pertuzumab combined with Herceptin and docetaxel are very encouraging and represent our commitment to developing potential new personalised options for people with this aggressive disease.
“We plan to submit the study results for global regulatory approval this year.”
Roche said that it would provide more detailed data at an upcoming medical conference later this year, and added that no new safety signals were observed and adverse events were consistent with those seen in previous studies.